Vascular growth factors of the placenta, apoptosis of blood neutrophils in pregnant women with post-COVID syndrome

Authors

DOI:

https://doi.org/10.18370/2309-4117.2023.70.23-26

Keywords:

COVID-19, pregnancy, apoptosis, endothelial growth factor, VEGF, placental growth factor, PIGF, interleukin-32α, IL-32α

Abstract

Research objectives: to determine the activity of vascular placental growth factors, apoptosis and necrosis of neutrophils in the blood of pregnant women with post-COVID syndrome.
Methods and materials. 30 pregnant women (the main group) with SARS-CoV-2, positive Ig A, M or G to SARS-CoV-2 at 30–34 weeks of pregnancy took part in the study. The control group consisted of 30 women with physiological pregnancy.
Blood neutrophils were studied by flow cytofluorometry. The proportion of neutrophils that were at the stage of apoptosis and necrosis was determined. The correlation of these indicators with the uncomplicated course of the gestational process during the physiological course of pregnancy and with the development of gestational complications against the background of post-COVID syndrome was determined.
In the third trimester of pregnancy, we collected blood samples to determine the effect of SARS-CoV-2 infection on placental angiogenesis. We evaluated a panel of biomarkers: vascular endothelial growth factor (VEGF), placental growth factor PlGF, and interleukin-32α (IL-32α).
Results. In pregnant women of the main group with a complicated course of pregnancy accompanied by post-COVID syndrome, apoptosis was at the level of 24.30 ± 0.50% of neutrophil cells, which was significantly different from the control group (4.45 ± 0.25%) (р < 0.001). The level of late apoptosis, necrosis of neutrophils increased 4 times – from 4.20 ± 0.65 to 16.80 ± 0.54% (р < 0.001). The concentration of IL-32α in pregnant women of the control group was 67.27 ± 5.63 pg/ml. Post-COVID syndrome caused an increase in this indicator in the main group by 2.8 times compared to the control group
(188.36 ± 25.22 pg/ml) (p < 0.001). In the III trimester, the concentration of VEGF reached maximum values in the main group and was 192.20 ±
10.02 pg/ml, which is 2 times higher than in the control group at the same time (95.30 ± 5.65 pg/ml), (p < 0.001). In the control group the level of PIGF at full-term pregnancy was 144.53 ± 15.55 pg/ml. In women with postpartum syndrome, PIGF significantly decreased and was 43.92 ± 4.81 pg/ml, which was only 30% of the PIGF value in women with an uncomplicated pregnancy (p < 0.001).
Conclusions. The development of metabolic disorders and apoptotic changes in the placental tissue are confirmed at the morphological level in the form of destructive and necrotic changes in the microcirculatory channel of the placenta. An increase in the level of annexin-positive neutrophils and activation of the degree of neutrophil necrosis is accompanied by fetoplacental dysfunction, by violation of the balance of placental growth factors and is an important marker for predicting of fetal growth retardation in pregnant women with post-COVID syndrome.

Author Biographies

A.V. Boichuk, Еducational and Scientific Institute of Postgraduate Education of I.Y. Horbachevskyi Ternopil State Medical University of the MOH of Ukraine, Ternopil

MD, professor, head of the Obstetrics and Gynaecology Department

Y.B. Yakymchuk, I.Y. Horbachevskyi Ternopil State Medical University, Ternopil

PhD, assistant professor, Therapeutics and Family Medicine Department

O.O. Shevchuk, I.Y. Horbachevskyi Ternopil State Medical University, Ternopil

MD, professor, Department of Pharmacology and Clinical Pharmacology

Sandor G. Vari, Cedars-Sinai Medical Center, Los Angeles

MD, International Research and Innovation in Medicine Program

References

  1. Blitz MJ, Gerber RP, GulersenM, et al. Preterm birth among women with and without severe acute respiratory syndrome coronavirus 2 infection. Acta Obstet Gynecol Scand. 2021 Dec; 100(12):2253–2259. DOI: 10.1111/aogs.14269.
  2. Aabakke AJM, Petersen TG, Wojdemann K, et al. Risk factors for and pregnancy outcomes after SARS-CoV-2 in pregnancy according to disease severity: A nationwide cohort study with validation of the SARS-CoV-2 diagnosis. Acta Obstet Gynecol Scand. 2023;102 (3):282–293. DOI: 10.1111/aogs.14512.
  3. Aimes RT, Zijlstra A, Hooper JD, et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost. 2003;89(3):561–72.
  4. Keskin A, Ustun GU, Aci R, Duran U. Homocysteine as a marker for predicting disease severity in patients with COVID-19. Biomark Med. 2022 May;16(7):559–68. DOI: 10.2217/bmm-2021-0688
  5. Menter T, Mertz KD, Jiang S, et al. Placental Pathology Findings during and after SARS-CoV-2 Infection: Features of Villitis and Malperfusion. Pathobiology. 2021;88(1):69–77. DOI: 10.1159/000511324
  6. Ponti G, Maccaferri M, Ruini C, et al. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020 Sep;57(6):389–99. DOI: 10.1080/10408363.2020.1770685.
  7. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May;395(10234):1417–8. DOI: 10.1016/S0140-6736(20)30937-5.
  8. Wong YP, Khong TY, Tan GC. The Effects of COVID-19 on Placenta and Pregnancy: What Do We Know So Far? Diagnostics (Basel). 2021 Jan; 11(1):94. DOI: 10.3390/diagnostics11010094.
  9. Rizzo G, Mappa I, Maqina P, et al. Effect of SARS-CoV-2 infection during the second half of pregnancy on fetal growth and hemodynamics: a prospective study. Acta Obstet Gynecol Scand. 2021; 100(6):1034–39. DOI: 10.1111/aogs.14130.
  10. Severinsen ER, Kähler LKA, Thomassen SE, et al. Mental health indicators in pregnant women compared with women in the general population during the coronavirus disease 2019 pandemic in Denmark. Acta Obstet Gynecol Scan. 2021 Nov;100(11):2009–18. DOI: 10.1111/aogs.14258.
  11. Aimes RT, Zijlstra A, Hooper JD, et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost. 2003;89(3):561–72.
  12. Alzamora MC, Paredes T, Caceres D, et al. Severe COVID-19 during pregnancy and possible vertical transmission. Am J Perinatol. 2020 Jun;37(8):861–5. DOI: 10.1055/s-0040-1710050.
  13. Bikdeli B, Madhavan MV, Gupta A, et al. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost. 2020 Jul;120(7):1004–24. DOI: 10.1055/s-0040-1713152.
  14. Blitz MJ, Gerber RP, Gulersen M, et al. Preterm birth among women with and without severe acute respiratory syndrome coronavirus 2 infection. Acta Obstetricia et Gynecologica Scandinavica, 2021 Dec; 100(12):2253–9. DOI: 10.1111/aogs.14269.
  15. [Internet]. Minfin. Available from: https://index. minfin.com.ua/reference/coronavirus/ukraine/.
  16. Kant Sahu K, Lal A, Kumar Mishra A. COVID-2019 and pregnancy: A plea for transparent reporting of all cases. Acta Obstetricia et Gynecologica Scandinavica, 2020 Jul; 99(7):951. DOI: 10.1111/aogs.13850.
  17. Melincovici CS, Boşca AB, Şuşman S, et al. Vascular endothelial growth factor (VEGF) – key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455–67.
  18. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med. 2020 Jul;144(7):799–805. DOI: 10.5858/arpa.2020-0901-SA.
  19. Wastnedge EAN, Reynolds RM, van Boeckel SR, et al. Pregnancy and COVID-19. Physiol Rev. 2021 Jan 1;101(1):303–18. DOI: 10.1152/physrev.00024.2020.
  20. Wenling Y, Junchao Q, Xiao Z, Ouyang S. Pregnancy and COVID-19: management and challenges. Rev Inst Med Trop Sao Paulo. 2020;62:e62. DOI: 10.1590/s1678-9946202062062.
  21. Cherenack, E.M, Salazar, A.S, Nogueira, N.F, et al. Infection with SARS-CoV-2 is associated with menstrual irregularities among women of reproductive age. PLoS One. 2022 Oct 26;17(10):e0276131. DOI: 10.1371/journal.pone.0276131.
  22. Wan, Y, Shang, J, Graham R, et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 2020 Mar 17;94(7):e00127–20. DOI: 10.1128/JVI.00127-20.
  23. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224): 565–74. DOI: 10.1016/S0140-6736(20)30251-8.
  24. Letko M, Munster V. Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV. bioRxiv. 2020 Jan 22. DOI: 10.1101/2020.01.22.915660.
  25. Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020 Mar 27;12(4):372. DOI: 10.3390/v12040372.

Downloads

Published

2023-12-29

How to Cite

Boichuk, A., Yakymchuk, Y., Shevchuk, O., & Vari, S. G. (2023). Vascular growth factors of the placenta, apoptosis of blood neutrophils in pregnant women with post-COVID syndrome. REPRODUCTIVE ENDOCRINOLOGY, (70), 23–26. https://doi.org/10.18370/2309-4117.2023.70.23-26

Issue

No. 70 (2023)

Section

Pregnancy and childbirth

License

Copyright (c) 2024 А.В. Бойчук, Ю.Б. Якимчук, О.О. Шевчук, Sandor G. Vari

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.